Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction

Clicks: 1
ID: 314975
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #73 of 102 articles by views in cardiovascular research

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to increase in prevalence and has limited treatment options. HFpEF is a systemic condition with a broad phenotype including diastolic dysfunction, pulmonary oedema, exercise intolerance, and left ventricular (LV) hypertrophy, collectively resulting in enhanced morbidity and mortality. The transcription factor RUNX1 has recently been identified as a mediator of pathological changes in multiple cardiac diseases, however its role in HFpEF remained unknown. Methods and Results Here we show that inhibition of Runx1 limits adverse cardiac remodelling in a clinically relevant mouse model of HFpEF. Cardiomyocyte-specific tamoxifen-inducible Runx1-deficient mice with HFpEF are protected, with preservation of diastolic function, and attenuation of pulmonary oedema, exercise intolerance, and hypertrophy. Furthermore, targeting Runx1 in HFpEF by using gene transfer or small molecule inhibitor Ro5-3335 improves diastolic function and reduces pulmonary oedema, both in female and male mice. Conclusion Overall, our research enhances our understanding of RUNX1 in cardiac disease and presents a novel translational target for the treatment of HFpEF.
Reference Key
openalex_W7162435150 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ali Ali Mohamed Elbassioni, Anmar Raheem, Jian Song, Alexander S. Johnston, Cara Trivett, Hong Lin, Haobo Zhang, Ashley Bradley, Erin Higgins, Cameron R Thomson, Leanne Mooney, Yen Chin Koay, Dylan O’Toole, Pawel Herzyk, Colin Nixon, Karen Blyth, Mark Hughes, J. O’Sullivan, Ninian N. Lang, Colin Berry, Thomas Braun, Gabriele G Schiattarella, Mauro Giacca, Martin McBride, Stuart A. Nicklin, Ewan R Cameron, Christopher M. Loughrey, Eilidh MacDonald
Journal cardiovascular research
Year 2026
DOI
10.1093/cvr/cvag106
URL
https://doi.org/10.1093/cvr/cvag106
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.